Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-masked, placebo-controlled Phase 2 study of MEDI-551 (inebilizumab) in neuromyelitis optica and neuromyelitis optica spectrum disorders
2014-000253-36Phase 2Terminated
- Sponsor
- MedImmune
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in neuromyelitis optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) comparing MEDI-551 (inebilizumab) with Placebo (2 arms). Primary endpoint: Time to NMO/NMOSD attack. Started Aug 2014; status: terminated.
02
Drugs
inebilizumab
03
Conditions
neuromyelitis optica (NMO)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2014-000253-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000253-36.